불면증 치료 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the insomnia treatment market size is expected to grow from USD 3.76 billion in 2025 to USD 3.95 billion in 2026 and is forecast to reach USD 5.07 billion by 2031 at 5.09% CAGR over 2026-2031.

This report is Segmented by Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), Insomnia Type (Primary Insomnia, Comorbid Insomnia), Patient Age Group (Paediatric, Adults, Geriatric), Care/Service Setting (Hospital In-Patient, Sleep Clinics & Specialty Centres, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Insomnia Treatment Market Trends and Insights

Aging population with comorbid sleep disorders

One in four adults aged 65-79 years reports chronic insomnia, versus 16% in younger cohorts. Age-related polypharmacy, cognitive decline, and cardiovascular comorbidities complicate care and elevate interest in orexin antagonists, which preserve sleep architecture without marked next-day impairment. The 2025 FDA approval of suvorexant for mild-to-moderate Alzheimer's dementia enlarged the elder addressable pool and validated age-specific dosing strategies. Pharma pipelines now prioritize geriatric-friendly formulations to capture this expanding segment.

Commercial launch of next-gen orexin antagonists

Daridorexant and lemborexant have shifted treatment focus from GABA modulation to orexin pathway inhibition, reducing sleep latency by up to 35 minutes and trimming wake-after-sleep onset by 29 minutes in pivotal trials. China's 2025 approval of DAYVIGO opened a 172.5 million-patient market, underscoring global appetite for this mechanism. Patent protection to 2033 shields innovators, giving them margin headroom and investment runway.

Patent expiries driving rapid generic erosion

Zolpidem's loss of exclusivity spawned 13 generic approvals and re-set price points, illustrating margin compression that typically reaches 80% within 18 months. Branded holders counter via extended-release formats and lifecycle tactics, but the effect remains a net drag on premium drug revenue. The 2024 sale of Ambien brands to Cosette for USD 39 million signals continuing though diminished brand equity in post-LOE environments.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of digital CBT-I platforms via telehealth
2. Expansion of digital CBT-I platforms via telehealth
3. Dependency & safety concerns of hypnotics

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The pharmacological segment generated 76.72% of insomnia treatment market revenue in 2025 given entrenched prescribing habits and rapid symptom relief expectations. Non-benzodiazepine Z-drugs and legacy benzodiazepines comprised most scripts, but orexin receptor antagonists captured a growing slice following multiple 2024-2025 approvals. Non-pharmacological solutions, led by digital CBT-I, delivered the fastest growth at a 5.39% CAGR, reflecting payer acceptance and consumer preference for non-drug options. Over-the-counter products, including cannabidiol, attracted self-medicating users reporting 62.9% sleep-quality improvement.

Converging care models now bundle drugs with sleep-coaching apps, remote monitoring, and behavioral nudges to optimize adherence. Prescription digital therapeutics cleared by the FDA validate reimbursement and set the stage for hybrid regimens that improve long-term efficacy. Companies with integrated platforms tap dual revenue streams while strengthening real-world evidence packages demanded by payers. The shift implies rising competition on holistic outcomes rather than molecule-level distinctions, rewarding firms that marry pharmacology with technology.

Primary insomnia delivered 61.88% of 2025 revenue yet grows slower than comorbid insomnia, which is forecast to expand at 5.98% CAGR and widen its contribution to the insomnia treatment market size through 2031. Multi-morbidity involving depression, anxiety, and cardiovascular disease calls for coordinated management strategies and favors medications with minimal interaction liabilities such as orexin antagonists. The 2025 label expansion of suvorexant to Alzheimer's dementia elevated disease-specific opportunities and spurred research into neurodegenerative comorbidities.

Digital therapeutics capable of addressing both insomnia and underlying mood disorders through targeted modules strengthen the value proposition for integrated care. Insurers increasingly reimburse bundled solutions that treat root causes, encouraging health-system partnerships. As healthcare shifts toward outcome-based reimbursement, comorbid cases become a strategic growth lever given their higher overall economic burden.

Complete Report Scope:

• By Treatment Type (Value)
  • Pharmacological Treatment
    • Prescription Drugs
      • Non-Benzodiazepines (Z-drugs)
      • Benzodiazepines
      • Orexin Receptor Antagonists
      • Melatonin Receptor Agonists
      • Antidepressants & Others
    • Over-the-Counter Drugs
  • Non-Pharmacological Treatment
    • Cognitive Behavioural Therapy
    • Device-based Therapy
• By Insomnia Type (Value)
  • Primary Insomnia
  • Comorbid Insomnia
• By Patient Age Group (Value)
  • Paediatric (0-17 yrs)
  • Adults (18-64 yrs)
  • Geriatric (>=65 yrs)
• By Care / Service Setting (Value)
  • Hospital In-patient
  • Sleep Clinics & Specialty Centres
  • Out-patient / Ambulatory Care
  • Homecare / Self-administratio
• By Geography (Value)
  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America's leadership rests on sophisticated payer systems, employer wellness integration, and the FDA's supportive stance toward digital therapeutics. North America accounted for 37.64% of 2025 revenue. Medicare covers key sleep studies but still excludes chronic insomnia polysomnography, encouraging uptake of lower-cost home studies. Europe provides reliable but slower growth; the EMA approved daridorexant yet rejected ramelteon, reflecting stringent evidence standards. Adoption gaps remain, with benzodiazepines often over-prescribed despite guideline limits.

Asia-Pacific outpaces other regions at a 6.63% CAGR; China's 2025 lemborexant launch and South Korea's ongoing daridorexant Phase 3 trial exemplify rapid regulatory movement. Japan's early embrace of orexin agents demonstrates high physician receptivity, while Australia's telehealth expansion widens rural access. Cannabinol products, legal since 2020 in Japan, present a parallel over-the-counter market and compel prescription brands to differentiate on clinical data. South America and the Middle East remain nascent but invest in diagnostic infrastructure, positioning them for above-average long-term growth. Multinationals cultivate local generics alliances to navigate pricing and distribution complexities in these regions.

1. Eisai
2. Merck
3. Idorsia Ltd
4. Sumitomo Pharma Co., Ltd.
5. Takeda Pharmaceuticals
6. Sanofi
7. Pfizer
8. Viatris
9. Teva Pharmaceutical Industries
10. Dr. Reddy's Laboratories Ltd.
11. Bayer
12. GlaxoSmithKline
13. Johnson & Johnson
14. Procter & Gamble
15. Reckitt Benckiser Group
16. Vanda Pharmaceuticals
17. H. Lundbeck
18. Eli Lilly and Company
19. Avadel Pharmaceuticals plc
20. Aurobindo Pharma Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising prevalence of stress-related insomnia
  • 4.2.2 Ageing population with comorbid sleep disorders
  • 4.2.3 Commercial launch of next-gen orexin antagonists
  • 4.2.4 Expansion of digital CBT-I platforms via telehealth
  • 4.2.5 Wearable-based phenotyping enabling personalised dosing
  • 4.2.6 Employer-sponsored sleep-health benefits boosting prescriptions
• 4.3 Market Restraints
  • 4.3.1 Patent expiries driving rapid generic erosion
  • 4.3.2 Dependency & safety concerns of hypnotics
  • 4.3.3 Shift to cannabis-based OTC sleep aids
  • 4.3.4 Tighter reimbursement scrutiny on long-term pharmacotherapy
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Supplier Power
  • 4.7.2 Buyer Power
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Treatment Type (Value)
  • 5.1.1 Pharmacological Treatment
    • 5.1.1.1 Prescription Drugs
      • 5.1.1.1.1 Non-Benzodiazepines (Z-drugs)
      • 5.1.1.1.2 Benzodiazepines
      • 5.1.1.1.3 Orexin Receptor Antagonists
      • 5.1.1.1.4 Melatonin Receptor Agonists
      • 5.1.1.1.5 Antidepressants & Others
    • 5.1.1.2 Over-the-Counter Drugs
  • 5.1.2 Non-Pharmacological Treatment
    • 5.1.2.1 Cognitive Behavioural Therapy
    • 5.1.2.2 Device-based Therapy
• 5.2 By Insomnia Type (Value)
  • 5.2.1 Primary Insomnia
  • 5.2.2 Comorbid Insomnia
• 5.3 By Patient Age Group (Value)
  • 5.3.1 Paediatric (0-17 yrs)
  • 5.3.2 Adults (18-64 yrs)
  • 5.3.3 Geriatric (>=65 yrs)
• 5.4 By Care / Service Setting (Value)
  • 5.4.1 Hospital In-patient
  • 5.4.2 Sleep Clinics & Specialty Centres
  • 5.4.3 Out-patient / Ambulatory Care
  • 5.4.4 Homecare / Self-administratio
• 5.5 By Geography (Value)
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Mexico
    • 5.5.1.3 Canada
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Eisai Co., Ltd.
  • 6.3.2 Merck & Co., Inc.
  • 6.3.3 Idorsia Ltd
  • 6.3.4 Sumitomo Pharma Co., Ltd.
  • 6.3.5 Takeda Pharmaceutical Company Limited
  • 6.3.6 Sanofi S.A.
  • 6.3.7 Pfizer Inc.
  • 6.3.8 Viatris Inc.
  • 6.3.9 Teva Pharmaceutical Industries Ltd.
  • 6.3.10 Dr. Reddy's Laboratories Ltd.
  • 6.3.11 Bayer AG
  • 6.3.12 GlaxoSmithKline plc
  • 6.3.13 Johnson & Johnson
  • 6.3.14 Procter & Gamble Co.
  • 6.3.15 Reckitt Benckiser Group plc
  • 6.3.16 Vanda Pharmaceuticals Inc.
  • 6.3.17 H. Lundbeck A/S
  • 6.3.18 Eli Lilly and Company
  • 6.3.19 Avadel Pharmaceuticals plc
  • 6.3.20 Aurobindo Pharma Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment